In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease.

Shobha Ramsubir 1 Takahiro Nonaka 2 Carmen Bedia Girbés 3 Stéphane Carpentier 3 Thierry Levade 3, 4 Jeffrey Medin 1, 2, 5, *
* Auteur correspondant
1 MBP - Department of Medical Biophysics
2 Division of Stem Cell and Developmental Biology
3 I2MR - Institut de médecine moléculaire de Rangueil
4 Laboratoire de Biochimie [Purpan]
5 Institute of Medical Science
Abstract : Farber disease is a rare lysosomal storage disorder (LSD) caused by a deficiency of acid ceramidase (AC) activity and subsequent accumulation of ceramide. Currently, there is no treatment for Farber disease beyond palliative care and most patients succumb to the disorder at a very young age. Previously, our group showed that gene therapy using oncoretroviral vectors (RV) could restore enzyme activity in Farber patient cells. The studies described here employ novel RV and lentiviral (LV) vectors that engineer co-expression of AC and a cell surface marking transgene product, human CD25 (huCD25). Transduction of Farber patient fibroblasts and B cells with these vectors resulted in overexpression of AC and led to a 90% and 50% reduction in the accumulation of ceramide, respectively. Vectors were also evaluated in human hematopoietic stem/progenitor cells (HSPCs) and by direct in vivo delivery in mouse models. In a xenotransplantation model using NOD/SCID mice, we found that transduced CD34(+) cells could repopulate irradiated recipient animals, as measured by CD25 expression. When virus was injected intravenously into mice, soluble CD25 was detected in the plasma and increased AC activity was present in the liver up to 14 weeks post-injection. These findings suggest that vector and transgene expression can persist long-term and offer the potential of a lasting cure. To our knowledge, this is the first report of in vivo testing of direct gene therapy strategies for Farber disease.
Type de document :
Article dans une revue
Molecular Genetics and Metabolism, Elsevier, 2008, 95 (3), pp.133-41. 〈10.1016/j.ymgme.2008.08.003〉
Liste complète des métadonnées
http://www.hal.inserm.fr/inserm-00409375
Contributeur : Marie Francoise Simon <>
Soumis le : vendredi 7 août 2009 - 10:27:52
Dernière modification le : jeudi 13 septembre 2018 - 10:26:05

Lien texte intégral

openaccess

Identifiants

Collections

UNIV-TLSE3

Citation

Shobha Ramsubir, Takahiro Nonaka, Carmen Bedia Girbés, Stéphane Carpentier, Thierry Levade, et al.. In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease.. Molecular Genetics and Metabolism, Elsevier, 2008, 95 (3), pp.133-41. 〈10.1016/j.ymgme.2008.08.003〉. 〈inserm-00409375〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

71

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD